SG301-SC Injection Safety Study in Subjects With Primary ITP Patients

Clinical trial NCT07710248 · RECRUITING

Trial details

NCT number: NCT07710248
Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Immune Thrombocytopenia

Start date: 2026-06-11
Primary completion: 2027-05-17
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.